Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | DNM1 | Q05193 | 8/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | RRM1 | P23921 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL996518 | 0.98 | ALDH1A1 (0.58) | ALDH1A1TDP1LMNADNM1MEN1 | |
| SCHEMBL20495968 | 0.93 | ALDH1A1 (0.64) | ALDH1A1TDP1LMNADNM1MEN1 | |
| SCHEMBL22342116 | 0.93 | ALDH1A1 (0.64) | ALDH1A1TDP1LMNADNM1MEN1 | |
| SCHEMBL4566012 | 0.93 | ALDH1A1 (0.64) | ALDH1A1TDP1LMNADNM1MEN1 | |
| SCHEMBL24200454 | 0.93 | ALDH1A1 (0.64) | ALDH1A1TDP1LMNADNM1MEN1 | |
| SCHEMBL24684882 | 0.93 | ALDH1A1 (0.64) | ALDH1A1TDP1LMNADNM1MEN1 | |
| SCHEMBL20495959 | 0.93 | ALDH1A1 (0.64) | ALDH1A1TDP1LMNADNM1MEN1 | |
| SCHEMBL22658086 | 0.93 | ALDH1A1 (0.64) | ALDH1A1TDP1LMNADNM1MEN1 | |
| SCHEMBL22766465 | 0.93 | ALDH1A1 (0.64) | ALDH1A1TDP1LMNADNM1MEN1 | |
| SCHEMBL10383392 | 0.93 | ALDH1A1 (0.64) | ALDH1A1TDP1LMNADNM1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3831372-A1 | MITOGUAZONE FOR PREVENTING THE RELAPSE OR THE PROGRESSION OF MULTIPLE SCLEROSIS | Pathologica LLC (US) | 2021-06-09 | — | — | EP | disclosed |
| CN-107163904-B | Hot melt adhesive consisting of high molecular weight polyamide resin, low molecular weight polyamide resin and grafted polyolefin resin and preparation method thereof | 南通协鑫热熔胶有限公司 | 2020-08-04 | — | — | CN | disclosed |
| US-10350178-B2 | Methods and compositions for treatment of demyelinating diseases | PATHOLOGICA LLC (US) | 2019-07-16 | — | — | US | disclosed |
| EP-3473247-A1 | COMPOSITION FOR ORAL DELIVERY COMPRISING MGBG FOR USE IN TREATING MULTIPLE SCLEROSIS | Pathologica LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| CN-104997762-B | Oral delivery drug comprising MGBG and the method for treating disease | 帕萨罗杰卡有限公司 | 2019-03-08 | — | — | CN | disclosed |
| CN-109432073-A | Purposes of the MGBG in the drug that preparation treats or prevents progressive MS and its progress | 帕萨罗杰卡有限公司 | 2019-03-08 | — | — | CN | disclosed |
| US-20180360783-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | PATHOLOGICA LLC | 2018-12-20 | — | — | US | disclosed |
| EP-2453886-B1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2018-12-12 | — | — | EP | disclosed |
| CN-105163730-B | Methods and compositions for treating demyelinating diseases | 帕萨罗杰卡有限公司 | 2018-10-30 | — | — | CN | disclosed |
| US-10085955-B2 | Methods and compositions for treatment of demyelinating diseases | PATHOLOGICA LLC (US) | 2018-10-02 | — | — | US | disclosed |
| CN-100582084-C | Hydrophobic polyamine analogs and methods for their use | MEDICKEST THERAPY CORP | 2010-01-20 | — | — | CN | disclosed |
| US-7432302-B2 | Composition containing polyamine transport inhibitor and use thereof | MEDIQUEST THERAPEUTICS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| EP-1373185-A4 | HYDROPHOBIC POLYAMINE ANALOGS AND METHODS FOR THEIR USE | MEDIQUEST THERAPEUTICS INC (US) | 2005-12-07 | — | — | EP | disclosed |
| US-6963010-B2 | Anticancer agents; osteoporosis; autoimmune disease | MEDIQUEST THERAPEUTICS, INC. (US) | 2005-11-08 | — | — | US | disclosed |
| US-20050245615-A1 | Composition containing polyamine transport inhibitor and use thereof | MEDIQUEST THERAPEUTICS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| US-20050176828-A1 | Hydrophobic polyamine analogs and methods for their use | MEDIQUEST THERAPEUTICS, INC. (US) | 2005-08-11 | — | — | US | disclosed |
| CN-1511137-A | Hydrophobic polyamine analogs and methods of use thereof | 麦迪凯斯特治疗学股份有限公司 | 2004-07-07 | — | — | CN | disclosed |
| EP-1373185-A2 | HYDROPHOBIC POLYAMINE ANALOGS AND METHODS FOR THEIR USE | Mediquest Therapeutics, Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030187276-A1 | Hydrophobic polyamine analogs and methods for their use | AMINEX THERAPEUTICS, INC. | 2003-10-02 | — | — | US | disclosed |
| WO-2002053519-A2 | HYDROPHOBIC POLYAMINE ANALOGS AND METHODS FOR THEIR USE | MEDIQUEST THERAPEUTICS, INC. (US) | 2002-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187276-A1 | Hydrophobic polyamine analogs and methods for their use | SRM, SMS, HNMT | ALDH1A1 2904/4885TDP1 695/4885LMNA 1571/4885 |
| US-10085955-B2 | Methods and compositions for treatment of demyelinating diseases | SRM, PMP22, SMS | ALDH1A1 2747/4885TDP1 247/4885LMNA 1715/4885 |
| US-20050176828-A1 | Hydrophobic polyamine analogs and methods for their use | SRM, SMS, HNMT | ALDH1A1 2904/4885TDP1 695/4885LMNA 1571/4885 |
| US-20050245615-A1 | Composition containing polyamine transport inhibitor and use thereof | SLC7A1, SRM, SLC16A1 | ALDH1A1 1242/4885TDP1 1487/4885LMNA 2140/4885 |
| US-20180360783-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | PMP22, MAG, GMFG | ALDH1A1 2637/4885TDP1 743/4885LMNA 2354/4885 |
| US-10350178-B2 | Methods and compositions for treatment of demyelinating diseases | PMP22, MAG, GMFG | ALDH1A1 2637/4885TDP1 743/4885LMNA 2354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.